Novartis halts UK trial of anticholesterol drug Leqvio

Novartis said on Wednesday that it had decided not to move forward with ORION-17, the UK-based primary prevention trial originally planned as part of its partnership with NHS England to investigate the potential of the anti-cholesterol drug Leqvio.

“After careful evaluation, we have decided not to move forward with ORION-17,” a spokesperson said in an emailed statement. “We continue to have very high ambitions for Leqvio and are encouraged by the foundation we have built and the traction we have seen so far, both in the UK and around the world.”

For more details, check out the link given below:

Novartis Not To Move Ahead With UK Trial Of Anti-Cholesterol Drug Leqvio

What do you think?

Written by

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Doctor gets barred from Practice over pending rural services, approaches high court

What Is Blood Sugar Level And How To Manage It For A Healthy Life